Bupropion For Reducing High-Risk Behaviors in Depressed Men Who Have Sex With Men (MSM)
Status:
Completed
Trial end date:
2004-09-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study was to test the whether high-risk, HIV-seronegative persons
with mild-to-moderate depression would be more likely to adopt protective behavior change
when provided with pharmacotherapy for their depression than when treated with placebo.
High-risk behaviors include using illegal drugs and participating in unprotected sexual
intercourse. The specific pharmacotherapy used in this study was the anti-depressant,
bupropion. The subject population consisted of HIV negative men who have sex with men (MSM)
with mild-to-moderate depression.
Phase:
Phase 1
Details
Lead Sponsor:
New York University NYU Langone Health
Collaborators:
GlaxoSmithKline National Institute on Drug Abuse (NIDA)